Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Multiple Myeloma 13Neoplasms, Plasma Cell 3Recurrence 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma of Lung 2Waldenstrom Macroglobulinemia 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Polyneuropathies 1Paraproteinemias 1Mouth Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Gliosarcoma 1Glioblastoma 1Endocrine System Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Temozolomide 19Radiotherapy 11Bevacizumab 7Radiation 4Irinotecan 4Erlotinib Hydrochloride 4carmustine, poliferprosan 20 drug combination 3Radiotherapy, Intensity-Modulated 3O(6)-benzylguanine 3Magnetic Resonance Spectroscopy 3Carmustine 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3Vorinostat 2Surgical Procedures, Operative 2Radiotherapy, Conformal 2Radiosurgery 2Gadolinium DTPA 2Filgrastim 2Drug Therapy 2Congresses as Topic 2Cilengitide 2Chemotherapy, Adjuvant 2Aminolevulinic Acid 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vitespin 1sargramostim 1sapanisertib 1poly ICLC 1plerixafor 1picropodophyllin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gliosarcoma × Thalidomide × Clear all
NCT00014443 2023-01-09

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Rush University Medical Center

Phase 2 Terminated
5 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡